Back to results
US 2011/0257138 A1Published application
Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases
OwnerHarold Greveinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerHarold Greveinventor
Estimating the term…
The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).
The use of at least one systemically administrable, in particular oral, monoterpene and at least one topically administrable, in particular inhalative, respiratory therapeutic for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or comedication, of respiratory disorders, in particular bronchopulmonary disorders.
The use as claimed in any of the preceding claims, characterized in that the monoterpene is administered in daily doses of from 100 to 2000 mg/die, in particular from 200 to 1200 mg/die, preferably from 300 to 1000 mg/die, and/or that the monoterpene is prepared for administration in a daily dose of from 100 to 2000 mg/die, in particular from 200 to 1200 mg/die, preferably from 300 to 1000 mg/die.
The use as claimed in any of the preceding claims, characterized in that the monoterpene is 1,8-cineol, where 1,8-cineol is employed in particular in the form of enteric capsules which dissolve in the small intestine, preferably in daily doses of from 100 to 2000 mg/die, in particular from 200 to 1200 mg/die, particularly preferably from 300 to 1000 mg/die.
The use as claimed in any of the preceding claims, characterized in that the respiratory therapeutic to be administered topically is an inhalative respiratory therapeutic.
The use as claimed in any of the preceding claims, characterized in that the respiratory therapeutic to be administered topically, in particular inhalatively, is selected from bronchodilators and bronchospasmolytics and/or the respiratory therapeutic to be administered topically, in particular inhalatively, is selected from the group consisting of (i) corticosteroids, in particular glucocorticoids;
The use as claimed in any of the preceding claims, characterized in that the respiratory therapeutic to be administered topically, in particular inhalatively, is a corticosteroid, in particular glucocorticoid, preferably selected from the group consisting of beclometasone, mometasone, budesonide, flunisolide, fluticasone, triamcinolone and their physiologically acceptable derivatives, in particular salts and esters, and also mixtures and combinations of the compounds mentioned above, where the corticosteroid is administered in particular in daily doses of from 50 to 1000 μg/die, in particular from 75 to 800 μg/die, particularly preferably from 100 to 600 μg/die, and/or is prepared in particular for administration in a daily dose of from 50 to 1000 μg/die, in particular from 75 to 800 μg/die, particularly preferably from 100 to 600 μg/die.
The use as claimed in any of the preceding claims, characterized in that the respiratory therapeutic to be administered topically, in particular inhalatively, is a sympathomimetic, in particular betasympathomimetic, preferably beta-2-sympathomimetic, in particular selected from the group consisting of short-acting betamimetics (SABA), in particular albuterol, fenoterol, hexoprenalin, levalbuterol, metaproterenol, orciprenalin, pirbuterol, reproterol, salbutamol and/or terbutalin, and long-acting betamimetics (LABA), in particular salmeterol and/or formoterol.
The use as claimed in any of the preceding claims, characterized in that the respiratory therapeutic to be administered topically, in particular inhalatively, is an anticholinergic, in particular from the group consisting of ipratropium, tiotropium and/or their physiologically acceptable derivatives, preferably salts, particularly preferably ipratropium bromide and/or tiotropium bromide.
The use as claimed in any of the preceding claims, characterized in that additionally at least one further systemic, in particular oral, active compound is administered, in particular selected from the group consisting of systemic phosphodiesterase inhibitors, in particular theophylline;
The use as claimed in any of the preceding claims, characterized in that the bronchopulmonary disorder is an inflammatory or non-inflammatory, in particular inflammatory, disorder of the upper or lower respiratory tract.
The use as claimed in any of the preceding claims, characterized in that the bronchopulmonary disorder is an inflammatory respiratory disorder, in particular a respiratory disorder which is infection-exacerbated and/or requires steroids for treatment.
The use as claimed in any of the preceding claims, characterized in that the bronchopulmonary disorder is bronchial asthma or bronchitis.
The use as claimed in any of the preceding claims, characterized in that the bronchopulmonary disorder is a chronic obstructive pulmonary disorder (COPD), in particular a chronic obstructive bronchitis or a pulmonary emphysema.
The use as claimed in any of the preceding claims, characterized in that the bronchopulmonary disorder is a tobacco smoke-induced, in particular nicotine-induced, acute or chronic respiratory inflammation.
The use as claimed in any of the preceding claims, characterized in that the bronchopulmonary disorder is an early form of COPD, in particular stage 0 or I according to GOLD, or an early form of bronchial asthma, in particular stage 0 or I according to GINA.
The use as claimed in any of the preceding claims for treating an early form of COPD, in particular stage 0 or I according to GOLD, or an early form of bronchial asthma, in particular stage 0 or I according to GINA, in particular for exacerbation prophylaxis before or after exacerbation and/or for prevention or slowing down of the progression of the disease before or after exacerbation.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, for the in particular synergistic enhancement of the activity of at least one topically administrable, in particular inhalative, respiratory therapeutic in the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, for the in particular synergistic enhancement of the anti-inflammatory and/or antioxidative activity of topical, in particular inhalative, corticosteroids, in particular glucocorticoids.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, for reducing the dose of topically administrable, in particular inhalative, respiratory therapeutics, preferably inhalative corticosteroids, in the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, for inducing and/or enhancing the steroid-permissive effect of topically administrable, in particular inhalative, respiratory therapeutics, preferably inhalative corticosteroids, in the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, for avoiding or reducing habituation to betasympathomimetics in the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders, in particular with continuous therapy of all degrees of severity of COPD and bronchial asthma.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, in combination with at least one topically administrable, in particular inhalative, respiratory therapeutic, in particular in combination with an inhalative corticosteroid, for reducing the need for or for replacing systemic corticosteroids or other anti-inflammatory and/or immunosuppressive systemic substances in the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, in particular as claimed in any of the preceding claims, in combination with at least one topically administrable, in particular inhalative, respiratory therapeutic, in particular in combination with an inhalative corticosteroid and optionally with an inhalative beta-2-sympathomimetic, to optimize the basic therapy of bronchial asthma and COPD.
The use as claimed in any of the preceding claims to treat systemic simultaneously affected organs in all severe forms of COPD.
The use as claimed in any of the preceding claims for modulating and inhibiting COPD-dependent and/or COPD-independent ageing processes, in particular with the aim of reducing morbidity, increasing the quality of life and/or life expectancy.
The use as claimed in any of the preceding claims, characterized in that the monoterpene, in particular 1,8-cineol, is used as an inducer of NO-production for the treatment of primary and secondary pulmonary-arterial hypertension (PAH) in COPD and bronchial asthma.
The use as claimed in any of the preceding claims, characterized in that the monoterpene, in particular 1,8-cineol, is used for improving tissue perfusion and/or microperfusion and also bronchodilation in NO-deficiency situations.
The use as claimed in any of the preceding claims, characterized in that the monoterpene, in particular 1,8-cineol, is used for inducing NO-production in recurrent infections of the upper and lower respiratory tracts or in infection-independent exacerbations, in particular owing to cigarette smoking and/or the action of ozone, or for normalizing noxious substance-dependent or -independent NO-deficiency situations.
The use as claimed in any of the preceding claims, characterized in that the monoterpene, in particular 1,8-cineol, is used as an antioxidant and/or NO-inducer in cigarette smoke-induced organ damage, in particular of the lung, the heart, the brain, the kidneys and the venous and arterial vascular system.
The use as claimed in any of the preceding claims, characterized in that the monoterpene, in particular 1,8-cineol, is used for the combined anti-inflammatory and/or antioxidative therapy of the persistent and/or progressive inflammation of the respiratory tract after cessation of smoking, if appropriate with comedication with other respiratory therapeutics, in particular with the aim of delaying the development of emphysemas, respiratory insufficiency and/or the development of peripheral airway obstructions.
The use as claimed in any of the preceding claims, characterized in that the monoterpene, in particular 1,8-cineol, is used for modulating the entire multiorgan ageing process by virtue of anti-inflammatory and/or antioxidative effects in an early long-term therapy.
The use of at least one systemically administrable, in particular oral, monoterpene and at least one topically administrable, in particular inhalative, respiratory therapeutic as combination therapeutic and/or for the purpose of comedication for the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders.
The use of at least one systemically administrable, in particular oral, monoterpene and at least one topically administrable, in particular inhalative, respiratory therapeutic for preparing a combination therapeutic, in particular in the form of a kit, for the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders.
A combination therapeutic, in particular in the form of a kit, preferably for the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders, comprising, firstly, at least one systemically administrable, in particular oral, monoterpene and, secondly, at least one topically administrable, in particular inhalative, respiratory therapeutic.
A method for treating the human or animal body, in particular a method for the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders, where at least one monoterpene and at least one respiratory therapeutic are each used in effective, in particular pharmaceutically effective, amounts, where the monoterpene is administered systemically, in particular orally, and the respiratory therapeutic is administered topically, in particular inhalatively.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, for the prophylactic and/or curative treatment of respiratory disorders, in particular bronchopulmonary disorders, in smokers and/or former smokers and for the preparation of a medicament for the prophylactic and/or curative treatment of respiratory disorders, in particular bronchopulmonary disorders, in smokers or former smokers, where the monoterpene can be employed in particular together with at least one topically administrable, in particular inhalative, respiratory therapeutic, in particular as a combination therapy and/or in comedication.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, for the prophylactic and/or curative treatment of antioxidative and/or anti-inflammatory processes in the human body in particular of smokers or for preparing a medicament for the prophylactic and/or curative treatment of antioxidative and/or anti-inflammatory processes in the body in particular of smokers, where the monoterpene can be employed in particular together with at least one topically administrable, in particular inhalative, respiratory therapeutic, in particular as a combination therapy and/or in comedication.
The use of at least one systemically administrable, in particular oral, monoterpene, preferably 1,8-cineol, for increasing the corticosteroid sensitivity of smokers, in particular for the prophylactic and/or therapeutic treatment of respiratory disorders, in particular bronchopulmonary disorders, where the monoterpene can be employed in particular together with at least one topically administrable, in particular inhalative, respiratory therapeutic, in particular as a combination therapy and/or in comedication.
Dependencies are inferred from the claim text.